Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


FDA clears deep transcranial magnetic stimulation device to treat obsessive-compulsive disorder


Brain­sWay’s Brain Stim­u­la­tion Device Receives FDA Approval to Treat Obses­sive-Com­pul­sive Dis­or­der (IEEE Spec­trum):

In 2013, Jerusalem-based Brain­sWay began mar­ket­ing a new type of brain stim­u­la­tion device that uses mag­net­ic puls­es to treat major depres­sive dis­or­der.

Now, thanks to pos­i­tive results in a study of 100 patients, the com­pa­ny has received approval from the U.S. Food and Drug Admin­is­tra­tion (FDA) to mar­ket the device for a sec­ond psy­chi­atric condition—obsessive-compulsive dis­or­der (OCD)

Typ­i­cal­ly, non­in­va­sive elec­tri­cal and mag­net­ic fields applied to the scalp, such as in tran­scra­nial direct cur­rent stim­u­la­tion (tDCS), affect wide swaths on the brain, acti­vat­ing every­thing in their path. The most pre­cise meth­ods, deep brain stim­u­la­tion tech­niques, require implant­i­ng an elec­trode deep into the brain.

The new device, how­ev­er, relies on deep tran­scra­nial mag­net­ic stim­u­la­tion (Deep-TMS) to stim­u­late deep brain struc­tures via pow­er­ful, care­ful­ly posi­tioned elec­tro­mag­nets. The Brain­sWay device stim­u­lates the brain at greater depth and breadth than oth­er TMS devices, claims com­pa­ny CEO Yaa­cov Mich­lin. “This allows us to non­in­va­sive­ly tar­get pre­vi­ous­ly unreach­able areas of the brain,” he says.

The Study:

BrainsWay’s FDA clear­ance for its OCD treat­ment was based on a piv­otal, mul­ti­cen­ter study demon­strat­ing that after six weeks of treat­ment, there was a sta­tis­ti­cal­ly sig­nif­i­cant improve­ment in the pri­ma­ry end­point results for the active treat­ment group when com­pared to sham (p=0.0127) … The study was con­duct­ed in a total of 11 med­ical cen­ters, with nine locat­ed in the Unit­ed States, one in Cana­da and one in Israel. Patients who did not suf­fi­cient­ly respond to phar­ma­co­log­i­cal or psy­cho­log­i­cal treat­ment were enrolled in the tri­al and con­tin­ued their phar­ma­co­log­i­cal or psy­cho­log­i­cal treat­ment dur­ing the study. The Brain­sWay OCD treat­ment pro­to­col con­sist­ed of twen­ty-minute ses­sions con­duct­ed five times per week, over the course of six weeks. Impor­tant­ly, a tai­lored provo­ca­tion was applied in each ses­sion to per­son­al­ize the treat­ment for the patients’ spe­cif­ic dis­or­der. Deep TMS treat­ment is non-inva­sive, requires no anes­the­sia and has been demon­strat­ed to be safe and well-tol­er­at­ed.”

More info in the press release

News in Context:

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Health & Wellness, Technology

Tags: , , , , , , , , ,

Search in our Archives

Follow us and Engage via…

RSS Feed

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Watch All Recordings Now (40+ Speakers, 12+ Hours)